|Systematic (IUPAC) name|
|Pregnancy cat.||? (US)|
|Mol. mass||366.4998 g/mol|
NSI-189 is a nootropic and neurogenic research chemical derived from nicotinamide and pyrazine created by Neuralstem, Inc. Research into NSI-189 has been heavily funded by the Defense Advanced Research Projects Agency (DARPA) and the National Institutes of Health (NIH).
NSI-189 has been shown to stimulate neurogenesis of human hippocampus-derived neural stem cells in vitro and in vivo. The hippocampus is responsible for the consolidation of information from short-term memory to long-term memory, along with spatial navigation.
NSI-189 has been shown to increase the hippocampal volume of healthy adult mice by 20%.
NSI-189 successfully completed a phase 1 clinical trial in 2011 where it was administered to 41 healthy volunteers, with no adverse effects reported.
Assuming positive outcomes in the phase 1b clinical trial, Neuralstem intends to pursue further clinical trials for a variety of encephalopathic conditions including major depressive disorder, traumatic brain injury, Alzheimer's disease, post-traumatic stress disorder, stroke and natural aging.
- SureCN9999791 - Compound Summary (CID 50922681)
- FDA Approves Neuralstem To Treat Final Cohort In NSI-189 Phase Ib Trial In Major Depressive Disorder
- The Pill That Could Cure Depression by Growing Your Brain
- Compositions to effect neuronal growth
- Why Neuralstem Could Provide A 10x Return
- Single-Dose Pharmacokinetics (PK) Study of Novel Neurogenic Compound NSI-189
- Multiple-Dose Pharmacokinetics (PK), and Pharmacodynamic (PD) Effect of NSI-189 Phosphate in Depression Patient Subjects